What’s Propelling Xbiotech Inc (NASDAQ:XBIT) After Lower Shorts Reported?




August 30, 2018 – By Lisa Delgado

XBiotech Inc. (NASDAQ:XBIT) Logo

The stock of Xbiotech Inc (NASDAQ:XBIT) registered a decrease of 1.51% in short interest. XBIT’s total short interest was 4.45 million shares in August as published by FINRA. Its down 1.51% from 4.52 million shares, reported previously. With 32,500 shares average volume, it will take short sellers 137 days to cover their XBIT’s short positions. The short interest to Xbiotech Inc’s float is 22.82%.

The stock increased 1.79% or $0.07 during the last trading session, reaching $3.97. About 2,967 shares traded. XBiotech Inc. (NASDAQ:XBIT) has declined 47.21% since August 30, 2017 and is downtrending. It has underperformed by 59.78% the S&P500.

XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company has market cap of $142.21 million. The company??s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It currently has negative earnings. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases.

More news for XBiotech Inc. (NASDAQ:XBIT) were recently published by: Nasdaq.com, which released: “XBiotech Announces Publication of Breakthrough Findings for Potential Role of Interleukin-1 alpha in Risk for Heart …” on August 27, 2018. Globenewswire.com‘s article titled: “XBiotech Highlights Quarterly Developments” and published on August 10, 2018 is yet another important article.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.



Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *